News
Wanbury bags key Brazil nod, eyes market expansion
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
- By IPP Bureau
| March 14, 2026
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA.
The latest clearance adds to the Sertraline hydrochloride Form I approval that the company already holds, further reinforcing its foothold in one of its key export markets. Wanbury currently commands a dominant 75% market share for sertraline in Brazil, and the new approval is expected to deepen that lead.
In a separate development, the company has also secured a commercial nod from a major client for a specialised grade of metformin DC grade, with potential business opportunity to be estimated around Rupees 15 crore per annum, as per the company.
The approval could translate into a new recurring revenue stream for the pharmaceutical firm, further boosting its active pharmaceutical ingredient (API) portfolio.
Wanbury also confirmed that its API manufacturing facilities remain compliant with global quality standards.
